...
首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Activation of mGlu1 but not mGlu5 metabotropic glutamate receptors contributes to postischemic neuronal injury in vitro and in vivo.
【24h】

Activation of mGlu1 but not mGlu5 metabotropic glutamate receptors contributes to postischemic neuronal injury in vitro and in vivo.

机译:mGlu1而不是mGlu5代谢型谷氨酸受体的激活在体外和体内均导致缺血后神经元损伤。

获取原文
获取原文并翻译 | 示例
           

摘要

In order to investigate the involvement of mGlu1 and mGlu5 metabotropic glutamate receptors in the development of postischemic neuronal death, we examined the effects of selective agonists and antagonists in models of cerebral ischemia in vitro and in vivo. In murine cortical cell cultures and rat organotypic hippocampal slices exposed to oxygen and glucose deprivation (OGD), the mGlu1 antagonists 1-aminoindan-1,5-dicarboxylic acid (AIDA; 300 &mgr;M), (S)-(+)-2-(3'-carboxybicyclo[1.1.1]pentyl)-glycine (CBPG; 300 &mgr;M), 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester (CPCCOEt; 10-30 &mgr;M) and (+)-2-methyl-4-carboxyphenylglycine (LY367385; 30-100 &mgr;M) reduced neuronal loss when added to the medium during OGD and the subsequent 24-h recovery period. On the contrary, the potent and selective mGlu5 antagonist methyl-6-(phenylethynyl)-pyridine (MPEP; 0.1-1 &mgr;M) did not exhibit neuroprotection in any of these in vitro models. Incubation with the nonselective mGlu1 and mGlu5 agonist 3,5-dihydroxyphenylglycine (3,5-DHPG; 300 &mgr;M) but not with the mGlu5 agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG; 1 mM) enhanced the severity of OGD-induced neuronal damage. In gerbils subjected to global ischemia, intracerebroventricular administration of AIDA (100 nmol two times) or CBPG (300 nmol, two times) afforded consistent protection against CA1 pyramidal cell death, whereas MPEP (10 pmol i.c.v two times and 10 mg/kg i.p two times) failed to reduce postischemic hippocampal damage. Our results suggest that activation of mGlu1 but not mGlu5 receptor contributes to postischemic neuronal injury.
机译:为了研究mGlu1和mGlu5代谢型谷氨酸受体在缺血后神经元死亡发展中的作用,我们研究了选择性激动剂和拮抗剂在体外和体内脑缺血模型中的作用。在鼠皮层细胞培养物中和暴露于氧和葡萄糖剥夺(OGD)的大鼠器官型海马切片中,mGlu1拮抗剂1-氨基茚满-1,5-二羧酸(AIDA; 300&mgr; M),(S)-(+)- 2-(3'-羧基双环[1.1.1]戊基)-甘氨酸(CBPG; 300μg,M),7-羟基亚氨基环丙烷[b] chromen-1a-羧酸乙酯(CPCCOEt; 10-30μg; M)和(+)-2-甲基-4-羧基苯基甘氨酸(LY367385; 30-100μM)在OGD和随后的24小时恢复期间添加到培养基中时,可减少神经元丢失。相反,有效的和选择性的mGlu5拮抗剂甲基-6-(苯基乙炔基)-吡啶(MPEP; 0.1-1&mgr; M)在任何这些体外模型中均未表现出神经保护作用。与非选择性mGlu1和mGlu5激动剂3,5-二羟基苯基甘氨酸(3,5-DHPG; 300μg; M)一起孵育,但与mGlu5激动剂(RS)-2-氯-5-羟基苯基甘氨酸(CHPG; 1 mM)一起孵育OGD引起的神经元损伤的严重程度。在遭受全球缺血的沙鼠中,对AIDA(两次100 nmol)或CBPG(两次300 nmol)的脑室内给药提供了针对CA1锥体细胞死亡的一致保护,而MPEP(两次10 pmol icv和两次两次10 mg / kg ip腹膜内给药)次)未能减轻缺血后海马的损害。我们的结果表明,mGlu1而不是mGlu5受体的激活有助于缺血后神经元损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号